PEG-coated gold nanoparticles attenuate β-adrenergic receptor-mediated cardiac hypertrophy

Int J Nanomedicine. 2017 Jul 3:12:4709-4719. doi: 10.2147/IJN.S130951. eCollection 2017.

Abstract

Gold nanoparticles (AuNPs) are widely used as a drug delivery vehicle, which can accumulate in the heart through blood circulation. Therefore, it is very important to understand the effect of AuNPs on the heart, especially under pathological conditions. In this study, we found that PEG-coated AuNPs attenuate β-adrenergic receptor (β-AR)-mediated acute cardiac hypertrophy and inflammation. However, both isoproterenol, a non-selective β-AR agonist, and AuNPs did not induce cardiac function change or cardiac fibrosis. AuNPs exerted an anti-cardiac hypertrophy effect by decreasing β1-AR expression and its downstream ERK1/2 hypertrophic pathway. Our results indicated that AuNPs might be safe and have the potential to be used as multi-functional materials (drug carrier systems and anti-cardiac hypertrophy agents).

Keywords: AuNPs; ERK1/2 signaling pathway; cardiac hypertrophy; β-adrenergic receptor.

MeSH terms

  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Agonists / toxicity
  • Animals
  • Cardiomegaly / drug therapy*
  • Cardiomegaly / metabolism
  • Fibrosis / chemically induced
  • Gold / pharmacokinetics
  • Gold / pharmacology
  • Heart / drug effects
  • Interleukin-6 / genetics
  • Isoproterenol / toxicity
  • MAP Kinase Signaling System / drug effects
  • Male
  • Mice, Inbred Strains
  • Myocardium / metabolism
  • Nanoparticles / administration & dosage
  • Nanoparticles / chemistry*
  • Polyethylene Glycols / chemistry
  • Receptors, Adrenergic, beta / genetics
  • Receptors, Adrenergic, beta / metabolism*
  • Receptors, Adrenergic, beta-1 / metabolism

Substances

  • Adrenergic beta-Agonists
  • Interleukin-6
  • Receptors, Adrenergic, beta
  • Receptors, Adrenergic, beta-1
  • Polyethylene Glycols
  • Gold
  • Isoproterenol